胰高血糖素样肽-1受体激动剂与慢性肝病合并2型糖尿病患者主要不良肝脏结局风险
该研究利用瑞典2010-2020年医疗登记数据模拟目标试验,比较胰高血糖素样肽-1受体激动剂(GLP1)启动者与未启动者10年主要不良肝脏结局(MALO)风险。意向性分析中10年MALO风险为13.3% vs 14.6%(RR=0.91,95%CI=0.50-1.32);符合方案分析中为7.4% vs 14.4%(RR=0.51,95%CI=0.14-0.88)。结论认为在持续治疗的患者中GLP1激动剂可能降低MALO风险,但需随机试验证实。
要点
- 意向性分析中GLP1启动者10年MALO风险13.3%(42/1026)vs 未启动者14.6%(1079/15633),RR=0.91(95%CI=0.50-1.32)。
- 符合方案分析中10年MALO风险7.4%(22/1026)vs 14.4%(1079/15633),RR=0.51(95%CI=0.14-0.88)。
- 符合方案分析6年MALO风险5.4%(21/1026)vs 9.0%(933/15633),RR=0.60(95%CI=0.29-0.90)。
核心结论
- 在持续治疗的慢性肝病合并2型糖尿病患者中,GLP1激动剂可能降低主要不良肝脏结局风险。
- GLP1激动剂是减少合并2型糖尿病患者慢性肝病进展风险的有前景药物,但需随机试验证实。
研究设计与样本
- 利用瑞典2010-2020年医疗登记观察数据模拟目标试验,纳入慢性肝病合并2型糖尿病合格患者。
- 采用逆概率加权边际结构模型比较GLP1激动剂启动者与未启动者的10年MALO参数估计风险。
- 随机抽取5%的未启动者以提高计算效率。
- MALO包括失代偿期肝硬化、肝细胞癌、肝移植或MALO相关死亡。
主要发现
- 意向性分析10年MALO风险:GLP1启动者13.3%(42/1026)vs 未启动者14.6%(1079/15633),RR=0.91(95%CI=0.50-1.32)。
- 符合方案分析10年MALO风险:GLP1启动者7.4%(22/1026)vs 未启动者14.4%(1079/15633),RR=0.51(95%CI=0.14-0.88)。
- 符合方案分析6年MALO风险:GLP1启动者5.4%(21/1026)vs 未启动者9.0%(933/15633),RR=0.60(95%CI=0.29-0.90)。
- 符合方案分析8年MALO风险:GLP1启动者7.2%(22/1026)vs 未启动者11.7%(1036/15633),RR=0.61(95%CI=0.21-1.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出该发现需在随机试验中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine the long-term causal effect of GLP1 agonists on the risk of major adverse liver outcomes (MALO) in patients with any chronic liver disease and type 2 diabetes. DESIGN: We used observational data from Swedish healthcare registers 2010-2020 to emulate a target trial of GLP1 agonists in eligible patients with chronic liver disease and type 2 diabetes. We used an inverse-probability weighted marginal structural model to compare parametric estimates of 10-year MALO risk (decompensated cirrhosis, hepatocellular carcinoma, liver transplantation or MALO-related death) in initiators of GLP1 agonists with non-initiators. We randomly sampled 5% of the non-initiators to increase computational efficiency. RESULTS: GLP1 agonist initiators had a 10-year risk of MALO at 13.3% (42/1026) vs 14.6% in non-initiators (1079/15 633) in intention-to-treat analysis (risk ratio (RR)=0.91, 95% CI=0.50 to 1.32). The corresponding 10-year per-protocol risk estimates were 7.4% (22/1026) and 14.4% (1079/15 633), respectively (RR=0.51, 95% CI=0.14 to 0.88). The per-protocol risk estimates at 6 years were 5.4% (21/1026) vs 9.0% (933/15 633) (RR=0.60, 95% CI=0.29 to 0.90) and at 8 years 7.2% (22/1026) vs 11.7% (1036/15 633) (RR=0.61, 95% CI=0.21 to 1.01). CONCLUSION: In patients with chronic liver disease and type 2 diabetes who adhered to therapy over time, GLP1 agonists may result in lower risk of MALO. This suggests that GLP1 agonists are promising agents to reduce risk of chronic liver disease progression in patients with concurrent type 2 diabetes, although this needs to be corroborated in randomised trials.
引用
- Wester A, Shang Y, Toresson Grip E, et al. Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes. Gut. 2024. PMID: 38253482. doi:10.1136/gutjnl-2023-330962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。